Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 24 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 12 |
| Mar 2026 | 0 | 13 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 25, 2021 22:58 UTC |
Maier Dennis BVice President, Operations
|
GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000055 · certent-form4.xml · nonDerivative · entry 1 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,092 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:56 UTC |
Mackin James PPresident & CEO
|
Tax withholdingCommon Stock | 4,383 | $25.41 | $111,372.03 |
DisclosureSEC source: 0000784199-21-000053 · certent-form4.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,431 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:56 UTC |
Mackin James PPresident & CEO
|
GrantCommon Stock | 28,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000053 · certent-form4.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,814 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:55 UTC |
LEE DAVID ASHLEYExecutive VP, COO & CFO
|
Tax withholdingCommon Stock | 1,237 | $25.41 | $31,432.17 |
DisclosureSEC source: 0000784199-21-000051 · certent-form4.xml · nonDerivative · entry 2 LEE DAVID ASHLEY · CIK 0001112830 · Executive VP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,118 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:55 UTC |
LEE DAVID ASHLEYExecutive VP, COO & CFO
|
GrantCommon Stock | 6,987 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000051 · certent-form4.xml · nonDerivative · entry 1 LEE DAVID ASHLEY · CIK 0001112830 · Executive VP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,355 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:53 UTC |
Horton AmyVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 619 | $25.41 | $15,728.79 |
DisclosureSEC source: 0000784199-21-000049 · certent-form4.xml · nonDerivative · entry 2 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,866 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:53 UTC |
Horton AmyVP, Chief Accounting Officer
|
GrantCommon Stock | 3,493 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000049 · certent-form4.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,485 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:49 UTC |
Holloway Jean FVP, General Counsel
|
Tax withholdingCommon Stock | 990 | $25.41 | $25,155.90 |
DisclosureSEC source: 0000784199-21-000047 · certent-form4.xml · nonDerivative · entry 2 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,904 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:49 UTC |
Holloway Jean FVP, General Counsel
|
GrantCommon Stock | 5,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000047 · certent-form4.xml · nonDerivative · entry 1 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,894 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:47 UTC |
Getz Matthew AVP, Human Resources
|
Tax withholdingCommon Stock | 563 | $25.41 | $14,305.83 |
DisclosureSEC source: 0000784199-21-000045 · certent-form4.xml · nonDerivative · entry 2 Getz Matthew A · CIK 0001784253 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,514 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:47 UTC |
Getz Matthew AVP, Human Resources
|
GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000045 · certent-form4.xml · nonDerivative · entry 1 Getz Matthew A · CIK 0001784253 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,077 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:44 UTC |
Davis John ESenior VP, Global Sales
|
Tax withholdingCommon Stock | 945 | $25.41 | $24,012.45 |
DisclosureSEC source: 0000784199-21-000043 · certent-form4.xml · nonDerivative · entry 2 Davis John E · CIK 0001653206 · Senior VP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,787 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:44 UTC |
Davis John ESenior VP, Global Sales
|
GrantCommon Stock | 5,335 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000043 · certent-form4.xml · nonDerivative · entry 1 Davis John E · CIK 0001653206 · Senior VP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,732 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:42 UTC |
Capps Scott BVP, Clinical Research
|
Tax withholdingCommon Stock | 563 | $25.41 | $14,305.83 |
DisclosureSEC source: 0000784199-21-000041 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,801 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:42 UTC |
Capps Scott BVP, Clinical Research
|
GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000041 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,364 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:41 UTC |
Barthold Franz PeterVP, Research & Development
|
Tax withholdingCommon Stock | 704 | $25.41 | $17,888.64 |
DisclosureSEC source: 0000784199-21-000039 · certent-form4.xml · nonDerivative · entry 2 Barthold Franz Peter · CIK 0001806854 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:41 UTC |
Barthold Franz PeterVP, Research & Development
|
GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000039 · certent-form4.xml · nonDerivative · entry 1 Barthold Franz Peter · CIK 0001806854 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,004 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:30 UTC |
Simpson Michael SSVP, Regulatory Affairs and QA
|
GrantStock Options (Right to Buy) · Derivative | 15,118 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000033 · certent-form4.xml · derivative · entry 2 Simpson Michael S · CIK 0001760902 · SVP, Regulatory Affairs and QA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,118 Underlying: Common Stock · 15,118 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:30 UTC |
Simpson Michael SSVP, Regulatory Affairs and QA
|
GrantCommon Stock | 5,355 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000033 · certent-form4.xml · nonDerivative · entry 1 Simpson Michael S · CIK 0001760902 · SVP, Regulatory Affairs and QA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,821 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
GrantStock Options (Right to Buy) · Derivative | 11,017 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · derivative · entry 6 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,017 Underlying: Common Stock · 11,017 shares Expires 2028-02-17 F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 6,630 | $21.55 Strike: $21.55 | $142,876.50 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · derivative · entry 5 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,630 shares Expires 2025-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 3/12/2019 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
GrantCommon Stock | 3,902 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · nonDerivative · entry 4 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,916 F3 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
SaleCommon Stock | 567 | $24.64 | $13,972.92 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · nonDerivative · entry 3 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,014 F2 · price: Reflects the price of $24.6436 the shares were sold. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at this price Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
SaleCommon Stock | 6,630 | $24.73 | $163,983.11 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · nonDerivative · entry 2 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,581 F1 · price: Reflects the price of $24.7335 the shares were sold. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at this price Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:28 UTC |
Maier Dennis BVice President, Operations
|
Exercise / conversionCommon Stock | 6,630 | $21.55 | $142,876.50 |
DisclosureSEC source: 0000784199-21-000031 · certent-form4.xml · nonDerivative · entry 1 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:26 UTC |
Mackin James PPresident & CEO
|
GrantStock Options (Right to Buy) · Derivative | 93,519 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000029 · certent-form4.xml · derivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,519 Underlying: Common Stock · 93,519 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:26 UTC |
Mackin James PPresident & CEO
|
GrantCommon Stock | 33,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000029 · certent-form4.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,399 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:23 UTC |
LEE DAVID ASHLEYExecutive VP, COO & CFO
|
GrantStock Options (Right to Buy) · Derivative | 22,025 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000027 · certent-form4.xml · derivative · entry 3 LEE DAVID ASHLEY · CIK 0001112830 · Executive VP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,025 Underlying: Common Stock · 22,025 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:23 UTC |
LEE DAVID ASHLEYExecutive VP, COO & CFO
|
GrantCommon Stock | 7,801 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000027 · certent-form4.xml · nonDerivative · entry 1 LEE DAVID ASHLEY · CIK 0001112830 · Executive VP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,368 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:22 UTC |
Horton AmyVP, Chief Accounting Officer
|
GrantStock Options (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000025 · certent-form4.xml · derivative · entry 2 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Common Stock · 10,516 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:22 UTC |
Horton AmyVP, Chief Accounting Officer
|
GrantCommon Stock | 3,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000025 · certent-form4.xml · nonDerivative · entry 1 Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,992 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Holloway Jean FVP, General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 19,247 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000023 · certent-form4.xml · derivative · entry 3 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,247 Underlying: Common Stock · 19,247 shares Expires 2028-02-17 F3 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Holloway Jean FVP, General Counsel
|
GrantCommon Stock | 6,817 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000023 · certent-form4.xml · nonDerivative · entry 2 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,305 F2 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Holloway Jean FVP, General Counsel
|
GrantCommon Stock | 14,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000023 · certent-form4.xml · nonDerivative · entry 1 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,488 F1 · shares: Represents share of restricted stock that vest 33 1/3 per year beginning on the first anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Getz Matthew AVP, Human Resources
|
GrantStock Options (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000021 · certent-form4.xml · derivative · entry 2 Getz Matthew A · CIK 0001784253 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Common Stock · 10,516 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Getz Matthew AVP, Human Resources
|
GrantCommon Stock | 3,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000021 · certent-form4.xml · nonDerivative · entry 1 Getz Matthew A · CIK 0001784253 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,901 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Davis John ESenior VP, Global Sales
|
GrantStock Options (Right to Buy) · Derivative | 17,008 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000019 · certent-form4.xml · derivative · entry 2 Davis John E · CIK 0001653206 · Senior VP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,008 Underlying: Common Stock · 17,008 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Davis John ESenior VP, Global Sales
|
GrantCommon Stock | 6,024 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000019 · certent-form4.xml · nonDerivative · entry 1 Davis John E · CIK 0001653206 · Senior VP, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,397 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC |
Capps Scott BVP, Clinical Research
|
GrantStock Options (Right to Buy) · Derivative | 10,016 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000017 · certent-form4.xml · derivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,016 Underlying: Common Stock · 10,016 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC |
Capps Scott BVP, Clinical Research
|
GrantCommon Stock | 3,548 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000017 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,188 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:12 UTC |
Barthold Franz PeterVP, Research & Development
|
GrantStock Options (Right to Buy) · Derivative | 10,016 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000015 · certent-form4.xml · derivative · entry 2 Barthold Franz Peter · CIK 0001806854 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,016 Underlying: Common Stock · 10,016 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:12 UTC |
Barthold Franz PeterVP, Research & Development
|
GrantCommon Stock | 3,548 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000015 · certent-form4.xml · nonDerivative · entry 1 Barthold Franz Peter · CIK 0001806854 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,828 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| December 31, 2020 Filed Jan 11, 2021 21:50 UTC |
Maier Dennis BVice President, Operations
|
Exercise / conversionESPP · Derivative | 170 | $16.18 Strike: $16.18 | $2,749.84 |
DisclosureSEC source: 0000784199-21-000006 · certent-form5.xml · derivative · entry 6 Maier Dennis B · CIK 0001742150 · Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2020 Filed Jan 11, 2021 21:47 UTC |
Holloway Jean FVP, General Counsel
|
Exercise / conversionESPP · Derivative | 189 | $16.18 Strike: $16.18 | $3,057.17 |
DisclosureSEC source: 0000784199-21-000004 · certent-form5.xml · derivative · entry 6 Holloway Jean F · CIK 0001540065 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC |
Capps Scott BVP, Clinical Research
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $9.97 Strike: $9.97 | $99,700.00 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/26/2015 Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC |
Capps Scott BVP, Clinical Research
|
SaleCommon Stock | 8,366 | $21.34 | $178,553.03 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,640 F1 · price: Reflects weighted average price. Range was from $21.25 to $21.45. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC |
Capps Scott BVP, Clinical Research
|
Exercise / conversionCommon Stock | 10,000 | $9.97 | $99,700.00 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:25 UTC |
MORGAN HARVEYDirector
|
GiftCommon Stock | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000222 · certent-form4.xml · nonDerivative · entry 2 MORGAN HARVEY · CIK 0001137972 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned indirectly by Spouse in a Revocable Trust Disclosed balance after: 42,697 Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:25 UTC |
MORGAN HARVEYDirector
|
GiftCommon Stock | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000222 · certent-form4.xml · nonDerivative · entry 1 MORGAN HARVEY · CIK 0001137972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,990 F1 · shares: 2,080 shares were gifted by the reporting person to a trust for the benefit of his spouse for no consideration. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:38 UTC |
McCall Ronald DDirector
|
SaleCommon Stock | 4,638 | $21.79 | $101,068.51 |
DisclosureSEC source: 0000784199-20-000218 · certent-form4.xml · nonDerivative · entry 1 McCall Ronald D · CIK 0001016766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,795 F1 · price: Reflects weighted average price. Range of prices were between $21.55 to $21.96. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.